BATON ROUGE, La., Nov. 13, 2017 — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer vaccine technology, targeted cancer therapies and commercialization of a portfolio of products internationally, today releases the latest data updating the  progression results at 19 weeks for all 20 patients, who have completed 6 vaccines in their Phase 1 clinical trial of ProscaVax for recurrent prostate cancer patients with increasing prostate specific antigen (PSA).  ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

All 20 patients enrolled in the trial completed ProscaVax therapy per protocol and have now completed the first follow-up at 19 weeks.  16 of 20 patients (80%) demonstrated stable disease/no prostate cancer progression.  Only four patients progressed during ProscaVax therapy (3 PSA progression, 1 radiological progression in the brain).

The safety review confirmed there were no drug-related serious adverse events or dose-limiting toxicities resulting from the vaccine therapy.

OncBioMune is awaiting additional follow-up data related to our previously disclosed study data.  This includes additional results on patients beyond the previously reported 12 of 15 patients that received ProscaVax vaccine, who exhibited an increased immune response to PSA as determined with a Lymphocyte Blastogenesis Assay.  Also, additional results on the 6 patients vaccinated after OncBioMune previously reported that 9 of 14 patients who received six ProscaVax vaccinations demonstrated increased PSA doubling times.  Additional follow-up will provide longer follow-up intervals for the last six patients who completed the vaccine therapy.

“All the data to date is consistent with previous study data showing ProscaVax elicits immune responses to fight tumor growth in prostate cancer,” said Dr. Jonathan Head, Chief Executive Officer at OncBioMune.  “We are impressed that 80 percent of the patients treated with ProscaVax demonstrated stable disease.  We look forward to continuing to follow the patients in this study to collect additional data and also to conducting a larger study to further validate the therapeutic benefit of our vaccine platform technology.”

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals’ actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals’ need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical’s vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact:

Andrew Kucharchuk
225 227 2384
akucha1.obmp@gmail.com